Formulation Supplied in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, 25% glycerol.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: This
product is stable at ≤ ‑70° C for up
to 1 year from the date of receipt. For optimal storage, aliquot into smaller
quantities after centrifugation and store at recommended temperature. Avoid repeated freeze-thaw cycles.
Active Kinase - Active JNK1 (0.1 μg/μL) diluted with Kinase Dilution Buffer and assayed as outlined in Figure 2. Note: These are suggested working dilutions. Optimal dilutions should be determined by each laboratory for each application.
Kinase Assay Buffer I, pH 7.2 - 25 mM MOPS, 12.5 mM beta -glycerolphosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA. Add 0.25 mM DTT to the Kinase Assay Buffer prior to use.
Kinase Dilution Buffer, pH 7.2 - Kinase Assay Buffer I diluted at a 1:4 ratio (5-fold dilution) with 50 ng/μL of BSA solution.
10 mM ATP Stock Solution - Prepare the ATP Stock Solution by dissolving 55 mg of ATP in 10 mL of Kinase Assay Buffer I.
[33P]-ATP Assay Cocktail - Prepare 250 μM [33P]-ATP Assay Cocktail in a designated radioactive work area by combining 150 μL of 10 mM ATP Stock Solution, 100 μL of [33P]-ATP (1 mCi/100 μL), and 5.75 mL of Kinase Assay Buffer I.
Substrate - ATF2 substrate prepared in buffer (50 mM Tris-HCl, pH 7.2, 50 mM NaCl, 5 mM EDTA, and 0.25 mM DTT) diluted in distilled or deionized water to a final concentration of 0.5 mg/mL.
Thaw the [33P]-ATP Assay Cocktail in a shielded container in a designated radioactive work area.
Thaw the Active JNK1, Kinase Assay Buffer I, Substrate, and Kinase Dilution Buffer on ice.
In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20 μL. a Diluted Active JNK1: 10 μL b. Substrate (1 mg/mL Stock Solution) 10 μL
Set up the blank control as outlined in step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled or deionized water.
Initiate the reaction by the addition of 5 μL [33P]-ATP Assay Cocktail, bringing the final volume up to 25 μL. Incubate the mixture in a water bath at 30 °C for 15 minutes.
After the 15 minute incubation period, terminate the reaction by spotting 20 μL of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (dilute 10 mL of phosphoric acid and make a 1 liter solution with distilled or deionized water) with constant gentle stirring. It is recommended that the strips be washed a total of three times for approximately 10 minutes each.
Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
Determine the corrected cpm by removing the blank control value (see step 4) for each sample and calculate the kinase specific activity as outlined below.
Calculation of [33P]-ATP Specific Activity (SA) (cpm/pmol) Specific Activity (SA) = cpm for 5 μL [33P]-ATP/pmol of ATP (in 5 μL of a 250 μM ATP stock solution; i.e. 1250 pmol)
Calculation of Kinase Specific Activity (SA) (pmol/minutes/μg or nmol/minutes/mg) Corrected cpm from reaction / [(SA of 33P-ATP in cpm/pmol) x (Reaction time in minutes) x (Enzyme amount in μg or mg)] x [(Reaction volume) / (Spot Volume)]
The approximate molecular weight is 70 kDa and the average purity is 83%.
JNK1 is a member of the MAP kinase group that is activated by dual phosphorylation on Threonine and Tyrosine residues during exposure to stress such as UV irradiation. JNK1 binds to the c-Jun transactivation domain and phosphorylates it on S63 and S73 (1). JNK1 has been shown to play an important role in disease processes. Activation of JNK1 results in defects in myotube viability and integrity leading to dystrophic myofiber destruction (2). JNK1 activity is also abnormally elevated in obesity and removal of JNK1 results in decreased adiposity and significantly improved insulin sensitivity.
Derijard, B. et al. (1994) Cell 76:1025.
Kolodziejczyk, S.M. et al. (2001) Curr. Biol. 11:1278.
C-Jun N-terminal Kinase 1
Entrez Gene IDs:
5599 (Human); 26420 (Mouse); 116554 (Rat)
c-Jun N-terminal kinase 1; EC 2.7.11; EC 184.108.40.206; JNK1 alpha protein kinase; JNK1 beta protein kinase; JNK1; JNK1JNK1A2; JNK-46; JUN N-terminal kinase; MAP kinase 8; MAPK 8; MAPK8; mitogen-activated protein kinase 8 isoform JNK1 alpha1; mitogen-activated protein kinase 8 isoform JNK1 beta2; mitogen-activated protein kinase 8; PRKM8; PRKM8JNK; protein kinase JNK1; SAPK1; SAPK1JNK21B1/2; Stress-activated protein kinase 1; Stress-activated protein kinase JNK1
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Have you used Recombinant Mouse Active JNK1 Protein, CF?
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.